HAE Share Price | Haemonetics Corp. Stock Analysis & Recommendation

Q: What does Haemonetics Corp. do?

Overview: Haemonetics Corporation is a healthcare company that provides products for the processing, handling, and analysis of blood, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.Financial Snapshot: Most recent Net Sales: 331 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 58 Million (Quarterly Results - Mar 2025) Market-cap: USD 3,315.03 Million (Small Cap)Key Metrics: P/E: 22.00 Dividend Yield: 0.00% Debt Equity: 1.13 Return on Equity: 18.58% Price to Book: 4.04Contact Details: Address: 125 SUMMER STREET, BOSTON MA: 02110 Tel: ['1 781 8487100', '1 781 3569763'] Website: https://www.haemonetics.com

Q: Who are in the management team of Haemonetics Corp.?

As of March 2022, the management team of Haemonetics Corp. includes the following individuals:- Mr. Richard Meelia, who serves as the Independent Chairman of the Board.- Mr. Christopher Simon, who is the President, Chief Executive Officer, and a Director.- Mr. Robert Abernathy, who is an Independent Director.- Ms. Catherine Burzik, who is also an Independent Director.- Mr. Michael Coyle, another Independent Director.- Mr. Charles Dockendorff, who serves as an Independent Director.- Dr. Mark Kroll, who is also an Independent Director.In summary, the management team consists of a mix of executive leadership and independent directors, with Mr. Christopher Simon at the helm as CEO.

Q: Is Haemonetics Corp. technically bullish or bearish?

As of 15 August 2025, the technical trend for Haemonetics Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators: the MACD is bearish on both weekly and monthly time frames, Bollinger Bands are bearish, and moving averages are also bearish on a daily basis. The KST and Dow Theory both reflect bearish sentiment on weekly and monthly scales. Additionally, the OBV shows a mildly bearish stance. Haemonetics has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -34.49% compared to the S&P 500's 12.22%, and a 1-year return of -32.35% versus 17.14% for the index.

Q: Is Haemonetics Corp. overvalued or undervalued?

As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company is currently undervalued, supported by a P/E ratio of 22, an EV to EBITDA of 13.04, and a PEG ratio of 8.36. In comparison, its peers show more favorable valuations, with Haemonetics' P/E ratio significantly lower than Masimo Corp. at 179.74 and Bio-Rad Laboratories, Inc. at 16.20.Despite its attractive valuation, Haemonetics has underperformed against the S&P 500, with a year-to-date return of -35.63% compared to the index's gain of 13.30%. This stark contrast in performance highlights the potential for recovery and value realization in Haemonetics Corp.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

150.26 k

Shareholding (Dec 2025)

FII

16.38%

Held by 143 FIIs

DII

26.45%

Held by 64 DIIs

Promoter

0.15%

How big is Haemonetics Corp.?

22-Jun-2025

As of Jun 18, Haemonetics Corp. has a market capitalization of 3,315.03 million, with net sales of 1,360.82 million and a net profit of 167.67 million over the latest four quarters. Shareholder's funds are 820.84 million, and total assets are 2,450.95 million.

View full answer

What does Haemonetics Corp. do?

22-Jun-2025

Haemonetics Corporation is a healthcare company specializing in blood processing, handling, and analysis products. As of March 2025, it reported net sales of $331 million and a net profit of $58 million, with a market cap of approximately $3.32 billion.

View full answer

Who are in the management team of Haemonetics Corp.?

22-Jun-2025

As of March 2022, Haemonetics Corp.'s management team includes CEO Christopher Simon and several independent directors, including Richard Meelia (Chairman), Robert Abernathy, Catherine Burzik, Michael Coyle, Charles Dockendorff, and Mark Kroll.

View full answer

Is Haemonetics Corp. technically bullish or bearish?

20-Sep-2025

As of August 15, 2025, Haemonetics Corp. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, moving averages, and underperformance against the S&P 500, with year-to-date returns of -34.49% compared to the index's 12.22%.

View full answer

Is Haemonetics Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Haemonetics Corp. is undervalued with a P/E ratio of 22 and an attractive valuation grade, despite a year-to-date return of -35.63%, indicating potential for recovery compared to the S&P 500's gain of 13.30%.

View full answer

Compare Haemonetics Corp. with Similar Stocks

Envista Holdings Corp.Lantheus Holdings, Inc.Masimo Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.96

Poor long term growth as Net Sales has grown by an annual rate of 7.32% and Operating profit at 8.03% over the last 5 years

Flat results in Jun 25

With ROCE of 12.30%, it has a attractive valuation with a 2.47 Enterprise value to Capital Employed

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,774 Million (Small Cap)

P/E

16.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.95

Return on Equity

19.13%

Price to Book

3.04

Revenue and Profits:

Net Sales:

339 Million

(Quarterly Results - Dec 2025)

Net Profit:

45 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-26.28%

6 Months

15.15%

1 Year

-8.94%

2 Years

-22.29%

3 Years

-23.12%

4 Years

2.83%

5 Years

-48.12%

Haemonetics Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

8.32%

EBIT Growth (5y)

15.08%

EBIT to Interest (avg)

8.96

Debt to EBITDA (avg)

2.49

Net Debt to Equity (avg)

1.13

Sales to Capital Employed (avg)

0.67

Tax Ratio

20.93%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

10.56%

ROE (avg)

14.77%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.04

EV to EBIT

14.93

EV to EBITDA

10.21

EV to Capital Employed

2.05

EV to Sales

2.76

PEG Ratio

0.57

Dividend Yield

ROCE (Latest)

13.73%

ROE (Latest)

19.13%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 109 Schemes (57.0%)

Foreign Institutions

Held by 143 Foreign Institutions (16.38%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 3.57% vs 1.84% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 15.50% vs 13.82% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "339.00",
          "val2": "327.30",
          "chgp": "3.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "96.90",
          "val2": "95.50",
          "chgp": "1.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.10",
          "val2": "7.20",
          "chgp": "12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "-8.80",
          "chgp": "82.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "44.70",
          "val2": "38.70",
          "chgp": "15.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "205.20%",
          "val2": "205.50%",
          "chgp": "-0.03%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 3.95% vs 12.01% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 42.60% vs 1.91% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,360.80",
          "val2": "1,309.10",
          "chgp": "3.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "337.90",
          "val2": "305.40",
          "chgp": "10.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.90",
          "val2": "16.50",
          "chgp": "-40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.10",
          "val2": "-43.80",
          "chgp": "95.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "167.70",
          "val2": "117.60",
          "chgp": "42.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "163.40%",
          "val2": "159.00%",
          "chgp": "0.44%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

339.00

327.30

3.57%

Operating Profit (PBDIT) excl Other Income

96.90

95.50

1.47%

Interest

8.10

7.20

12.50%

Exceptional Items

-1.50

-8.80

82.95%

Consolidate Net Profit

44.70

38.70

15.50%

Operating Profit Margin (Excl OI)

205.20%

205.50%

-0.03%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 3.57% vs 1.84% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 15.50% vs 13.82% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1,360.80

1,309.10

3.95%

Operating Profit (PBDIT) excl Other Income

337.90

305.40

10.64%

Interest

9.90

16.50

-40.00%

Exceptional Items

-2.10

-43.80

95.21%

Consolidate Net Profit

167.70

117.60

42.60%

Operating Profit Margin (Excl OI)

163.40%

159.00%

0.44%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 3.95% vs 12.01% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 42.60% vs 1.91% in Mar 2024

All Annual Results

Company CV

About Haemonetics Corp.

Haemonetics Corp.

Pharmaceuticals & Biotechnology

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Company Coordinates

Company Details

125 SUMMER STREET , BOSTON MA : 02110

Tel: 1 781 84871001 781 3569763

https://www.haemonetics.com

Registrar Details